AR118131A1 - Composición farmacéutica que comprende compuesto derivado de benzoimidazol - Google Patents
Composición farmacéutica que comprende compuesto derivado de benzoimidazolInfo
- Publication number
- AR118131A1 AR118131A1 ARP200100446A ARP200100446A AR118131A1 AR 118131 A1 AR118131 A1 AR 118131A1 AR P200100446 A ARP200100446 A AR P200100446A AR P200100446 A ARP200100446 A AR P200100446A AR 118131 A1 AR118131 A1 AR 118131A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition including
- derivative compound
- recurrence
- benzoimidazole derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a una composición farmacéutica para prevenir la recurrencia de la enfermedad por reflujo gastroesofágico, que comprende un derivado de benzoimidazol. La composición farmacéutica de la presente puede prevenir de manera eficaz la recurrencia de la enfermedad por reflujo gastroesofágico sin ningún efecto secundario durante un largo período de tiempo. Reivindicación 1: La composición farmacéutica para prevenir la recurrencia de la enfermedad por reflujo gastroesofágico, que comprende tegoprazán que es un compuesto representado por la fórmula química (1) o una sal farmacéuticamente aceptable del mismo en una cantidad de 25 mg en forma de tegoprazán.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190018801 | 2019-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118131A1 true AR118131A1 (es) | 2021-09-22 |
Family
ID=72143624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200100446A AR118131A1 (es) | 2019-02-18 | 2020-02-18 | Composición farmacéutica que comprende compuesto derivado de benzoimidazol |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220125764A1 (es) |
EP (1) | EP3927340A4 (es) |
JP (2) | JP2022520276A (es) |
KR (1) | KR20200100552A (es) |
CN (1) | CN113473984A (es) |
AR (1) | AR118131A1 (es) |
AU (1) | AU2020225520A1 (es) |
BR (1) | BR112021016212A2 (es) |
CA (1) | CA3130562A1 (es) |
EA (1) | EA202192286A1 (es) |
JO (1) | JOP20210226A1 (es) |
MX (1) | MX2021009893A (es) |
SG (1) | SG11202108949PA (es) |
UY (1) | UY38588A (es) |
WO (1) | WO2020170106A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3203701A1 (en) * | 2020-12-30 | 2022-07-07 | Min Jung Kim | Pharmaceutical composition comprising tegoprazan and non-steroidal anti-inflammatory drugs |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007072146A1 (en) * | 2005-12-19 | 2007-06-28 | Pfizer Japan Inc. | Chromane substituted benzimidazoles and their use as acid pump inhibitors |
EP3305291B1 (en) * | 2015-06-08 | 2021-05-19 | HK inno.N Corporation | Uses of benzimidazole derivative for nocturnal acid breakthrough |
KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
KR101829706B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 산부가염 |
KR101960357B1 (ko) * | 2016-12-26 | 2019-03-20 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체를 포함하는 신규한 제제 |
-
2020
- 2020-02-17 MX MX2021009893A patent/MX2021009893A/es unknown
- 2020-02-17 CA CA3130562A patent/CA3130562A1/en active Pending
- 2020-02-17 JO JOP/2021/0226A patent/JOP20210226A1/ar unknown
- 2020-02-17 US US17/429,732 patent/US20220125764A1/en active Pending
- 2020-02-17 BR BR112021016212-7A patent/BR112021016212A2/pt unknown
- 2020-02-17 JP JP2021547865A patent/JP2022520276A/ja active Pending
- 2020-02-17 CN CN202080015631.4A patent/CN113473984A/zh active Pending
- 2020-02-17 WO PCT/IB2020/051296 patent/WO2020170106A1/en unknown
- 2020-02-17 EP EP20759153.8A patent/EP3927340A4/en active Pending
- 2020-02-17 AU AU2020225520A patent/AU2020225520A1/en active Pending
- 2020-02-17 KR KR1020200018849A patent/KR20200100552A/ko not_active Application Discontinuation
- 2020-02-17 SG SG11202108949PA patent/SG11202108949PA/en unknown
- 2020-02-17 EA EA202192286A patent/EA202192286A1/ru unknown
- 2020-02-18 UY UY0001038588A patent/UY38588A/es unknown
- 2020-02-18 AR ARP200100446A patent/AR118131A1/es unknown
-
2023
- 2023-07-07 JP JP2023111840A patent/JP2023126955A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020225520A1 (en) | 2021-10-14 |
BR112021016212A2 (pt) | 2021-10-05 |
CA3130562A1 (en) | 2020-08-27 |
EP3927340A1 (en) | 2021-12-29 |
MX2021009893A (es) | 2021-09-14 |
US20220125764A1 (en) | 2022-04-28 |
JOP20210226A1 (ar) | 2023-01-30 |
SG11202108949PA (en) | 2021-09-29 |
UY38588A (es) | 2020-09-30 |
CN113473984A (zh) | 2021-10-01 |
EA202192286A1 (ru) | 2021-11-18 |
KR20200100552A (ko) | 2020-08-26 |
EP3927340A4 (en) | 2022-11-02 |
JP2022520276A (ja) | 2022-03-29 |
WO2020170106A1 (en) | 2020-08-27 |
JP2023126955A (ja) | 2023-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
CO2023008018A2 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
AR117814A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
AR099134A1 (es) | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
UY32490A (es) | Inhibidores de beta-secretasa | |
CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
CO2022001862A2 (es) | Regímenes de dosificación para inhibidores orales del factor d del complemento | |
MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
AR105319A1 (es) | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico | |
AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
CO6480931A2 (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas. | |
AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
ES2478447T3 (es) | Formulaciones del ácido desoxicólico y sus sales | |
AR118131A1 (es) | Composición farmacéutica que comprende compuesto derivado de benzoimidazol |